TICKERNERD
Menu
JSPRJSPRHealthcare · Biotechnology

JSPR Stock Forecast: Jasper Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.72
+3.88% on the day

The 6 Wall Street analysts covering Jasper Therapeutics, Inc. hold a median 12-month price target of $4 — +457.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$23.8M
Ticker Nerd rank
38 / 100
Median analyst target
$4.00
Analysts covering
6
Total return, dividends reinvested
1W
−9.1%
1M
−6.8%
YTD
−60.8%
1Y
−75.7%
From 52W high
−75.7%
From 52W low
+110.6%
$0.34
$2.96
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JSPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jasper Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Growth
87
Revisions
68
Issuance
63
Accruals
41
Momentum
18
Volatility
11
Quality
10
Value
9

Size (88): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

JSPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JSPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26JSPRHigh $20.00Median $4.00Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
3 Buy3 Hold0 Sell
Low $1.50Median $4.00High $20.00

The green dot is the last close — the median target sits +457.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026Piper SandlerInitiatesOverweight$2.00
15 May 2026RBC CapitalMaintainsSector Perform$4.00 → $3.00
15 May 2026RBC CapitalMaintainsSector Perform—
15 May 2026TD CowenDowngradeHold—
15 May 2026TD CowenDowngradeHold—
1 Apr 2026Evercore ISI GroupMaintainsOutperform—
23 Mar 2026UBSAssumesNeutral$1.50
11 Nov 2025RBC CapitalMaintainsSector Perform—
22 Sept 2025BTIGMaintainsBuy—
22 Sept 2025Evercore ISI GroupMaintainsOutperform—
22 Sept 2025JMP SecuritiesMaintainsMarket Outperform—
15 Aug 2025UBSMaintainsBuy—
8 July 2025BMO CapitalDowngradeMarket Perform—
8 July 2025Evercore ISI GroupMaintainsOutperform—
8 July 2025JMP SecuritiesMaintainsMarket Outperform—
7 July 2025BTIGMaintainsBuy—
7 July 2025Cantor FitzgeraldDowngradeNeutral—
7 July 2025HC Wainwright & Co.MaintainsBuy—
7 July 2025William BlairDowngradeMarket Perform—
15 May 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JSPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

JSPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Jasper Therapeutics, Inc. (JSPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
—
Price / book
5.9×

Cheaper than 18% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−244.2%

Higher than 6% of US stocks

Return on assets
−112.2%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

JSPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
JSPRJasper Therapeutics, Inc.$23.8M
38
CNSYCerenome, Inc.$23.3M
19
CLRBCellectar Biosciences, Inc.$24.5M
25
MRKRMarker Therapeutics, Inc.$23.2M
59
ENLVEnlivex Ltd.$24.7M
31
TVRDTvardi Therapeutics, Inc.$24.8M
28
CVMCEL-SCI Corp.$24.8M
34

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jasper Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest JSPR news & analysis

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 14 Aug 2026positive

Jasper Therapeutics reported its second quarter 2026 financial results and provided a corporate update. The company noted that its acquisition of Kira Pharmaceuticals closed in July, creating a combined company with a portfolio of clinical stage assets focused on immunologically-driven disorders.

Why it matters — JSPR watchers would care because the completed Kira Pharmaceuticals acquisition meaningfully expands the company's clinical-stage pipeline in immunologically-driven disorders.

FAQ

Frequently asked questions about JSPR stock

What is the JSPR stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Jasper Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JSPR stock a buy right now?

Of the 6 analysts covering Jasper Therapeutics, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Jasper Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JSPR?

As at 22 Aug 2026, Jasper Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will JSPR stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +457.1% from the last close, and Ticker Nerd's factor model ranks Jasper Therapeutics, Inc. 38 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JSPR stock forecast for 2030?

No analyst covering Jasper Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JSPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $20 over the next 12 months.

How has JSPR stock performed over the past year?

Jasper Therapeutics, Inc. returned -75.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jasper Therapeutics, Inc. do?

Jasper Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for disease treatment, particularly in the field of hematopoietic cell transplantation, autoimmune diseases, and chronic immune disorders.

What is the latest news on JSPR?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update". Jasper Therapeutics reported its second quarter 2026 financial results and provided a corporate update. The company noted that its acquisition of Kira Pharmaceuticals closed in July, creating a combined company with a portfolio of clinical stage assets focused on immunologically-driven disorders.

Company

About Jasper Therapeutics, Inc.

Jasper Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for disease treatment, particularly in the field of hematopoietic cell transplantation, autoimmune diseases, and chronic immune disorders. The company's approach relies on targeted technologies aimed at improving the safety and effectiveness of blood and immune system replacement therapies. This is critical in medical procedures like bone marrow transplants where the treatment preconditioning traditionally includes high-dose chemotherapy or radiation, posing significant risks to patients. Jasper Therapeutics strives to provide safer and more effective alternatives, thereby offering a potentially transformative impact on patient outcomes in these sectors. As an entity within the biotechnology industry, its developments have significant implications for healthcare advancements and patient care methodologies. Jasper Therapeutics is strategically positioned within the biotech market, making substantial contributions through its research and development efforts towards better treatment paradigms in its niche areas.

CEO Mr. Jeetinder Singh Mahal M.B.A. · 22 employees · United States · https://jaspertx.com